Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION
Fatal and/or serious hepatotoxicity occurred in 16% to 18% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig as recommended [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Fatal and/or serious pneumonitis occurred in 4% of Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Fatal and/or serious infections occurred in 21% to 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig for intestinal perforation [see WARNINGS AND PRECAUTIONS].
Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ.
The chemical name for idelalisib is 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4(3H)-one. It has a molecular formula of C22H18FN7O and a molecular weight of 415.42 g/mol. Idelalisib has the following structural formula:
 |
Idelalisib is a white to off-white solid with a pH-dependent aqueous solubility ranging from <0.1 mg/mL at pH 5-7 to over 1 mg/mL at pH 2 under ambient conditions.
Zydelig (idelalisib) tablets are for oral administration. Each tablet contains either 100 mg or 150 mg of idelalisib with the following inactive ingredients: microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, magnesium stearate and a tablet coating. The tablet coating consists of polyethylene glycol, talc, polyvinyl alcohol, and titanium dioxide and of FD&C Yellow #6/Sunset Yellow FCF Aluminum Lake (for the 100 mg tablet) and red iron oxide (for the 150 mg tablet).
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas.
Zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas.
The recommended dosage of Zydelig is 150 mg administered orally twice daily with or without food until disease progression or unacceptable toxicity. The optimal and safe dosing regimen for patients who receive treatment longer than several months is unknown.
Swallow tablets whole.
If a planned dose of Zydelig is missed by less than 6 hours, take the missed dose as soon as possible and take the next dose as usual. If a dose of Zydelig is missed by more than 6 hours, skip the missed dose and take the next dose at the usual time.
Table 1 presents the dosage modification for specific adverse reactions.
For other severe or life-threatening adverse reactions, withhold Zydelig until resolution. If resuming Zydelig after interruption for other severe or life-threatening toxicities, reduce the dosage to 100 mg orally twice daily. Permanently discontinue Zydelig for recurrence of other severe or life-threatening Zydelig-related toxicity upon rechallenge.
Table 1 : Dosage Modifications for Adverse Reactions
| ALT/AST | >3-5 x ULN | >5-20 x ULN | >20 x ULN |
| [see WARNINGS AND PRECAUTIONS] | Maintain Zydelig dose. Monitor at least weekly until ≤1 x ULN. | Withhold Zydelig. Monitor at least weekly until ALT/AST are ≤1 x ULN, then may resume Zydelig at 100 mg BID. | Discontinue Zydelig permanently. |
| Bilirubin | >1.5-3 x ULN | >3-10 x ULN | >10 x ULN |
| [see WARNINGS AND PRECAUTIONS] | Maintain Zydelig dose. Monitor at least weekly until ≤1 x ULN. | Withhold Zydelig. Monitor at least weekly until bilirubin is ≤1 x ULN, then may resume Zydelig at 100 mg BID. | Discontinue Zydelig permanently. |
| Diarrhea* | Moderate diarrhea | Severe diarrhea or hospitalization | Life-threatening diarrhea |
| [see WARNINGS AND PRECAUTIONS] | Maintain Zydelig dose. Monitor at least weekly until resolved. | Withhold Zydelig. Monitor at least weekly until resolved, then may resume Zydelig at 100 mg BID. | Discontinue Zydelig permanently. |
| Pneumonitis | Any symptomatic pneumonitis | ||
| [see WARNINGS AND PRECAUTIONS] | Discontinue Zydelig in patients with any severity of symptomatic pneumonitis. | ||
| Infections | Grade 3 or higher sepsis or pneumonia | ||
| [see WARNINGS AND PRECAUTIONS] | Interrupt Zydelig until infection has resolved. | ||
| Evidence of CMV infection or viremia | |||
| Interrupt Zydelig in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved. If Zydelig is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly. | |||
| Evidence of PJP infection | |||
| Interrupt Zydelig in patients with suspected PJP infection of any grade. Permanently discontinue Zydelig if PJP infection is confirmed. | |||
| [see WARNINGS AND PRECAUTIONS] | Permanently discontinue Zydelig in patients who experience intestinal perforation. | ||
| Severe Cutaneous Reactions | Suspected/Confirmed SJS, TEN, DRESS, or other severe or life-threatening (Grade >3) cutaneous reactions | ||
| [see WARNINGS AND PRECAUTIONS] | Interrupt Zydelig in patients with suspected SJS, TEN, or DRESS until the etiology of the reaction has been determined. Permanently discontinue Zydelig in patients with confirmed SJS, TEN, or DRESS, or other severe or life-threatening (Grade >3) cutaneous reactions. | ||
| Hypersensitivity Reactions | Evidence of hypersensitivity reactions | ||
| [see WARNINGS AND PRECAUTIONS] | Permanently discontinue Zydelig in patients who develop serious hypersensitivity reactions. | ||
| Neutropenia | ANC 1.0 to <1.5 Gi/L | ANC 0.5 to <1.0 Gi/L | ANC <0.5 Gi/L |
| [see WARNINGS AND PRECAUTIONS] | Maintain Zydelig dose. | Maintain Zydelig dose. Monitor ANC at least weekly. | Interrupt Zydelig. Monitor ANC at least weekly until ANC ≥0.5 Gi/L, then may resume Zydelig at 100 mg BID. |
| Thrombocytopenia | Platelets 50 to <75 Gi/L | Platelets 25 to <50 Gi/L | Platelets <25 Gi/L |
| [see ADVERSE REACTIONS] | Maintain Zydelig dose. | Maintain Zydelig dose. Monitor platelet counts at least weekly. | Interrupt Zydelig. Monitor platelet count at least weekly. May resume Zydelig at 100 mg BID when platelets ≥25 Gi/L. |
| Abbreviations: ANC: absolute neutrophil count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; ULN, upper limit of normal; CMV, cytomegalovirus; DRESS, drug reaction with eosinophilia and systemic symptoms; PCR: polymerase chain reaction; PJP: Pneumocystis jirovecii pneumonia; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis | |||
Abbreviations: ANC: absolute neutrophil count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; ULN, upper limit of normal; CMV, cytomegalovirus; DRESS, drug reaction with eosinophilia and systemic symptoms; PCR: polymerase chain reaction; PJP: Pneumocystis jirovecii pneumonia; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis
*Moderate diarrhea: increase of 4–6 stools per day over baseline; severe diarrhea: increase of ≥7 stools per day over baseline.
No dosage modification is recommended for lymphocytosis, which has been observed in some patients taking Zydelig. This observed lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings.
Zydelig tablets supplied as follows:
| Tablet Strength | Package Configuration | NDC No. | Description of Tablet; Debossed on Tablet |
| 150 mg | High density polyethylene (HDPE) bottle with a polyester fiber coil, capped with a child-resistant closure. Each bottle contains 60 film-coated tablets. | 61958-1702-1 | Oval shaped; pink; “150” on one side and “GSI” on the other side |
| 100 mg | 61958-1701-1 | Oval-shaped; orange; “100” on one side and “GSI” on the other side |
Store between 20–30 °C (68–86 °F) with excursions permitted 15–30 °C (59–86 °F).
Manufactured and distributed by: Gilead Sciences, Inc., Foster City, CA 94404 GSI and Zydelig are trademarks or registered trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. Revised: Feb 2022
The following clinically significant adverse reactions are described elsewhere in the labeling.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to Zydelig at a dosage of 150 mg twice daily in 110 patients administered in combination with rituximab in Study 312-0116, and in combination with other drugs in 380 patients. Among 490 patients who received Zydelig, 74% were exposed for 6 months or longer and 50% were exposed for one year or longer. In this pooled safety population, the most common (> 30%) adverse reactions were diarrhea, pneumonia, pyrexia, fatigue, rash, cough, and nausea. Common laboratory abnormalities were neutropenia, ALT elevations and AST elevations.
The safety data reflect exposure to Zydelig from two randomized, double-blind clinical trials (Studies 312-0116 and 312-0115) in 634 patients with relapsed CLL [see Clinical Studies] and one randomized, open-label trial in 259 patients with relapsed CLL (Study 312-0119).
Patients with relapsed CLL received up to 8 doses of rituximab (R) with (n=110) or without Zydelig (n=108)150 mg twice daily. The median duration of exposure to Zydelig was 8 months.
Serious adverse reactions were reported in 65 (59%) patients treated with Zydelig + R The most frequent serious adverse reactions reported for patients treated with Zydelig + R were pneumonia (23%), diarrhea (10%), pyrexia (9%), sepsis (8%), and febrile neutropenia (5%).
Adverse reactions that led to discontinuation of Zydelig occurred in 19 (17%) patients. The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.
Forty-two (38%) patients had dose interruptions and sixteen (15%) patients had dose reductions due to adverse reactions or laboratory abnormalities. The most common reasons for dose interruptions or reductions were pneumonia, diarrhea or colitis, rash, and elevated transaminases.
Table 2 and Table 3 summarize common adverse reactions and laboratory abnormalities reported for Zydelig + R and placebo + R arms.
Table 2 : Adverse Reactions Reported in ≥5% of Patients with CLL and Occurred at ≥2% Higher Incidence in Patients Receiving Zydelig in Study 312-0116
| Adverse Reaction | Zydelig + R N=110 (%) |
Placebo + R N=108(%) |
||
| Any Grade | Grade ≥3 | Any Grade | Grade ≥3 | |
| General disorders and administration site conditions | ||||
| pyrexia | 44 (40) | 3 (3) | 20 (19) | 1 (1) |
| chills | 27 (25) | 2 (2) | 17 (16) | 0 |
| pain | 8 (7) | 0 | 1 (1) | 0 |
| Gastrointestinal disorders | ||||
| diarrheaa | 35 (32) | 12 (11) | 20 (19) | 0 |
| nausea | 30 (27) | 1 (1) | 25 (23) | 0 |
| abdominal painb | 20 (18) | 1 (1) | 17 (16) | 2 (2) |
| vomiting | 17 (15) | 0 | 9 (8) | 0 |
| gastroesophageal reflux disease | 11 (10) | 1 (1) | 0 | 0 |
| stomatitis | 7 (6) | 2 (2) | 1 (1) | 0 |
| Respiratory, thoracic, and mediastinal disorders | ||||
| pneumoniac | 33 (30) | 23 (21) | 20 (19) | 14 (13) |
| Skin and subcutaneous tissue disorders | ||||
| rashd | 27 (25) | 4 (4) | 7 (6) | 1 (1) |
| Metabolism and Nutrition Disorders | ||||
| decreased appetite | 18 (16) | 2 (2) | 12 (11) | 2 (2) |
| dehydration | 7 (6) | 3 (3) | 0 | 0 |
| Infections and infestations | ||||
| sepsise | 10 (9) | 10 (9) | 4 (4) | 4 (4) |
| sinusitis | 9 (8) | 0 | 6 (6) | 0 |
| urinary tract infection | 9 (8) | 1 (1) | 4 (4) | 2 (2) |
| bronchitis | 8 (7) | 1 (1) | 5 (5) | 1 (1) |
| oral herpes | 6 (5) | 1 (1) | 3 (3) | 0 |
| Psychiatric disorders | ||||
| insomnia | 10 (9) | 0 | 7 (6) | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| arthralgia | 9 (8) | 1 (1) | 4 (4) | 0 |
| Nervous system disorders | ||||
| lethargy | 6 (5) | 0 | 2 (2) | 0 |
| a Diarrhea includes the following preferred terms: diarrhea, colitis. b Abdominal pain includes the following preferred terms: abdominal pain, abdominal pain upper, abdominal pain lower. c Pneumonia includes the terms: pneumonia, pneumonitis, lung infection, lung infiltration, pneumocystis jiroveci pneumonia, pneumonia legionella, lung infection pseudomonal, pneumonia fungal, respiratory tract infection, lower respiratory tract infection, and lower respiratory tract infection bacterial. d Rash includes the following preferred terms: dermatitis exfoliative, drug eruption, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, rash morbilliform, and exfoliative rash. e Sepsis includes the terms: sepsis, septic shock, neutropenic sepsis, and sepsis syndrome |
||||
Table 3 : Hematologic and Hepatic Laboratory Abnormalities Reported in ≥10% of Patients with CLL and Occurred at ≥5% Higher Incidence in Patients Receiving Zydelig in Study 312-0116
| Laboratory Parameter | Zydelig + R N=110 (%) |
Placebo + R N=108 (%) |
||
| Any Grade | Grade 3-4 | Any Grade | Grade 3-4 | |
| Hematology abnormalities | ||||
| neutropenia | 71 (65) | 46 (42) | 61 (56) | 33 (31) |
| leukopenia | 34 (31) | 9 (8) | 25 (23) | 9 (8) |
| lymphocytopenia | 23 (21) | 11 (10) | 13 (12) | 4 (4) |
| Serum chemistry abnormalities | ||||
| ALT increased | 43 (39) | 10 (9) | 13 (12) | 1 (1) |
| AST increased | 31 (28) | 6 (5) | 16 (15) | 0 |
After closure of Study 312-0116, 71 patients continued treatment with Zydelig on an extension study (Study 312-0117). The median duration of exposure was 18 months.
Serious adverse reactions occurred in 48 (68%) patients. The most frequent serious adverse reactions reported were pneumonia (30%), diarrhea (15%), and pyrexia (11%).
The most frequent adverse reactions were pneumonia (51%), pyrexia (46%), and cough (45%). The most frequent Grade 3 or greater adverse reactions were pneumonia (30%), diarrhea (15%), and sepsis (10%).
In Study 312-0119, 259 patients with relapsed CLL received up to 12 doses of ofatumumab with or without Zydelig 150 mg orally twice daily. Zydelig in combination with ofatumumab is not indicated for the treatment of relapsed CLL. The median duration of exposure to Zydelig was 13.9 months.
Serious adverse reactions were reported in 133 (77%) patients treated with Zydelig + ofatumumab. The most frequent serious adverse reactions reported were pneumonia (14%), pyrexia (13%), and diarrhea (12%).
Adverse reactions that led to discontinuation of Zydelig occurred in 71 (41%) patients.
One hundred and ten (64%) patients had dose interruptions and 42 (24%) patients had dose reductions due to adverse reactions or laboratory abnormalities. The most common reasons for dose discontinuations, reductions, or interruptions were diarrhea and colitis.
The most common adverse reactions were diarrhea (55%), pyrexia (38%), nausea (34%), and fatigue (34%).
In Study 312-0115, patients with relapsed CLL received up to 6 cycles of bendamustine and rituximab (BR) with or without Zydelig 150 mg orally twice daily. Zydelig in combination with bendamustine and rituximab is not indicated for the treatment of relapsed CLL. The median duration of exposure to Zydelig was 18.2 months.
Serious adverse reactions were reported in 147 (71%) patients treated with Zydelig + BR. The most frequent serious adverse reactions reported for patients treated with Zydelig + BR were febrile neutropenia (21%), pneumonia (17%), pyrexia (12%), and diarrhea (6%).
Adverse reactions that led to discontinuation of Zydelig occurred in 68 (33%) patients.
The most common adverse reactions that led to treatment discontinuations were pneumonia, diarrhea, and pyrexia.
One hundred twenty-two (59%) patients treated with Zydelig + BR had dose interruptions and 34 (16%) patients had dose reductions due to adverse reactions. The most common reasons for dose interruptions or reductions were increased ALT and diarrhea.
The most common adverse reactions were neutropenia (64%), pyrexia (43%), and diarrhea (41%).
The safety data reflect exposure to Zydelig from three open-label clinical trials (Studies 101-09, 101-02, and 101-10 in 146 patients with indolent non-Hodgkin lymphoma (iNHL) treated with Zydelig 150 mg orally twice daily. Zydelig is not indicated for the treatment of iNHL. The median duration of exposure was 6.1 months (range 0.3 to 26.4 months).
Serious adverse reactions were reported in 73 (50%) patients. The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).
Adverse reactions resulted in interruption or discontinuation for 78 (53%) patients. The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).
The most common adverse reactions were neutropenia (53%), ALT increased (50%), diarrhea (47%), AST increased (41%), fatigue (30%), nausea and cough (29% each), anemia and pyrexia (28% each), abdominal pain and thrombocytopenia (26% each), and pneumonia (25%).
Zydelig is not indicated for patients with indolent non-Hodgkin lymphoma or previously untreated CLL either as monotherapy or in combination with rituximab or BR. Safety data described below reflect exposure to Zydelig in three randomized, double-blind clinical trials (Studies 312-0123, 313-0124, and 313-0125) in patients with CLL and iNHL.
In Study 312-0123 (NCT01980888), 311 patients with previously untreated CLL received up to 6 cycles of BR with or without Zydelig 150 mg twice daily.
In Study 313-0124 (NCT01732913), 295 patients with previously treated iNHL [FL 66%, marginal zone lymphoma (MZL) 19%, SLL 9%, lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) 6%] received 8 doses of R with or without Zydelig 150 mg twice daily. Patients had a median of one prior therapy.
In Study 313-0125 (NCT01732926), 475 patients with previously treated iNHL (FL 63%, MZL 15%, SLL 11%, LPL/WM 11%) received up to 6 cycles of BR with or without
Zydelig 150 mg twice daily. Patients had a median of two prior therapies.
These three studies were terminated early due to a higher incidence of fatal and/or serious adverse reactions observed in patients treated with Zydelig in combination with R or BR. The most frequent serious adverse reactions were in the system organ classes of infections and infestations, blood and lymphatic system disorders, and gastrointestinal disorders.
The following adverse reactions have been identified during postapproval use of Zydelig. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)
Table 6 lists the potential effects of the coadministration of strong CYP3A modulators on Zydelig.
Table 6 : Drug Interactions with Zydelig that affect Idelalisib Concentrations
| Strong CYP3A Inhibitors | |
| Clinical Impact |
|
| Prevention or Management |
|
| Strong CYP3A Inducers | |
| Clinical Impact |
|
| Prevention or Management | Avoid coadministration of Zydelig with strong CYP3A4 inducers. |
The coadministration of Zydelig with a CYP3A substrate may increase the concentrations of this CYP3A substrate. Avoid coadministration of Zydelig with sensitive CYP3A substrates [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Fatal and/or serious hepatotoxicity occurred in 16% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies. Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred [see ADVERSE REACTIONS]. These findings were generally observed within the first 12 weeks of treatment and were reversible with dose interruption. After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations. Discontinue Zydelig for recurrent hepatotoxicity.
Avoid concurrent use of Zydelig with other drugs that may cause liver toxicity.
Monitor ALT and AST in all patients every 2 weeks for the first 3 months of treatment, every 4 weeks for the next 3 months, then every 1 to 3 months thereafter. Monitor weekly for liver toxicity if the ALT or AST rises above 3 times the upper limit of normal until resolved. Withhold Zydelig if the ALT or AST is greater than 5 times the upper limit of normal, and continue to monitor AST, ALT and total bilirubin weekly until the abnormality is resolved [see DOSAGE AND ADMINISTRATION].
Severe diarrhea or colitis (Grade 3 or higher) occurred in 20% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies [see ADVERSE REACTIONS]. Diarrhea can occur at any time. Avoid concurrent use of Zydelig and other drugs that cause diarrhea. Diarrhea due to Zydelig responds poorly to antimotility agents. Median time to resolution ranged between 1 week and 1 month across trials, following interruption of Zydelig therapy and in some instances, use of corticosteroids [see DOSAGE AND ADMINISTRATION].
Fatal and serious pneumonitis occurred in patients treated with Zydelig [see ADVERSE REACTIONS]. Clinical manifestations included interstitial infiltrates and organizing pneumonia. In randomized clinical trials of combination therapies, pneumonitis occurred in 4% of patients treated with Zydelig compared to 1% on the comparator arms. Time to onset of pneumonitis ranged from <1 to 15 months. Monitor patients on Zydelig for pulmonary symptoms. In patients taking Zydelig who present with pulmonary symptoms such as cough, dyspnea, hypoxia, interstitial infiltrates on a radiologic exam, or a decline by more than 5% in oxygen saturation, interrupt Zydelig until the etiology has been determined.
If symptomatic pneumonitis or organizing pneumonia is diagnosed, initiate appropriate treatment with corticosteroids and permanently discontinue Zydelig [see DOSAGE AND ADMINISTRATION].
Fatal and/or serious infections occurred in 48% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies [see ADVERSE REACTIONS]. The most common infections were pneumonia, sepsis, and febrile neutropenia. Treat infections prior to initiation of Zydelig therapy. Monitor patients on Zydelig for signs and symptoms of infection, and interrupt Zydelig for Grade 3 or higher infection [see DOSAGE AND ADMINISTRATION].
Serious or fatal Pneumocystis jirovecii pneumonia (PJP) or cytomegalovirus (CMV) occurred in <1% of patients treated with Zydelig. Provide PJP prophylaxis during treatment with Zydelig. Interrupt Zydelig in patients with suspected PJP infection of any grade, and permanently discontinue Zydelig if PJP infection of any grade is confirmed. Regular clinical and laboratory monitoring for CMV infection is recommended in patients with history of CMV infection or positive CMV serology at the start of treatment with Zydelig. Interrupt Zydelig in the setting of positive CMV PCR or antigen test until the viremia has resolved. If Zydelig is subsequently resumed, patients should be monitored by PCR or antigen test for CMV reactivation at least monthly [see DOSAGE AND ADMINISTRATION].
Fatal and serious intestinal perforation occurred in Zydelig-treated patients. At the time of perforation, some patients had moderate to severe diarrhea. Advise patients to promptly report any new or worsening abdominal pain, chills, fever, nausea, or vomiting. Discontinue Zydelig permanently in patients who experience intestinal perforation.
Fatal cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have occurred in patients treated with Zydelig. Cases of drug reaction with eosinophilia and systemic symptoms (DRESS) have also occurred [see ADVERSE REACTIONS]. Zydelig is contraindicated in patients with a history of toxic epidermal necrolysis [see CONTRAINDICATIONS]. If SJS, TEN, or DRESS is suspected, interrupt Zydelig until the etiology of the reaction has been determined. If SJS, TEN, or DRESS is confirmed, permanently discontinue Zydelig [see DOSAGE AND ADMINISTRATION].
Other severe or life-threatening (Grade ≥3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in patients treated with Zydelig. Monitor patients for the development of other severe or life-threatening cutaneous reactions and permanently discontinue Zydelig [see DOSAGE AND ADMINISTRATION].
Serious hypersensitivity reactions, including anaphylaxis, have been reported in patients on Zydelig. Zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis [see CONTRAINDICATIONS]. In patients who develop serious hypersensitivity reactions, permanently discontinue Zydelig [see DOSAGE AND ADMINISTRATION] and institute appropriate supportive measures.
Grade 3 or 4 neutropenia occurred in 58% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies [see ADVERSE REACTIONS]. Monitor blood counts at least every 2 weeks for the first 6 months of therapy, and at least weekly in patients while neutrophil counts are less than 1.0 Gi/L. Interrupt Zydelig until resolution and resume at reduced dose [see DOSAGE AND ADMINISTRATION].
Based on findings in animals and its mechanism of action, Zydelig may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of idelalisib to pregnant rats during organogenesis caused decreased fetal weight and congenital malformations at systemic exposures 12 times those reported in patients at the recommended dose of 150 mg twice daily.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Zydelig and for 1 month after the last dose [see Use In Specific Populations].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Advise patients that Zydelig can cause significant elevations in liver enzymes, and that serial testing of serum liver tests (ALT, AST, and bilirubin) are recommended while taking Zydelig [see WARNINGS AND PRECAUTIONS]. Advise patients to report symptoms of liver dysfunction including jaundice, bruising, abdominal pain, or bleeding.
Advise patients that Zydelig may cause severe diarrhea or colitis and to notify their healthcare provider immediately if the number of bowel movements in a day increases by six or more [see WARNINGS AND PRECAUTIONS].
Advise patients of the possibility of pneumonitis, and to report any new or worsening respiratory symptoms including cough or dyspnea [see WARNINGS AND PRECAUTIONS].
Advise patients that Zydelig can cause serious infections that may be fatal. Advise patients to immediately report symptoms of infection (e.g. pyrexia) [see WARNINGS AND PRECAUTIONS].
Advise patients of the possibility for intestinal perforation and to notify their healthcare provider immediately if they experience severe abdominal pain [see WARNINGS AND PRECAUTIONS].
Advise patients that Zydelig may cause severe cutaneous reactions and to notify their healthcare provider immediately if they develop a severe skin reaction [see WARNINGS AND PRECAUTIONS].
Advise patients that anaphylaxis can occur during treatment with Zydelig and to notify their healthcare provider immediately if they experience a hypersensitivity reaction, including anaphylaxis [see WARNINGS AND PRECAUTIONS].
Advise patients of the need for periodic monitoring of blood counts. Advise patients to notify their healthcare provider immediately if they develop a fever or any signs of infection [see WARNINGS AND PRECAUTIONS].
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
Advise females of reproductive potential to use effective contraception during treatment with Zydelig and for 1 month after the last dose [see Use In Specific Populations].
Advise males with female partners of reproductive potential to use effective contraception during treatment with Zydelig and for 3 months after receiving the last dose [see Use In Specific Populations].
Advise women not to breastfeed during treatment with Zydelig and for 1 month after the last dose [see Use In Specific Populations].
Advise patients to take Zydelig exactly as prescribed and not to change their dose or to stop taking Zydelig unless they are told to do so by their healthcare provider. Zydelig may be taken with or without food. Zydelig tablets should be swallowed whole. Advise patients that if a dose of Zydelig is missed by less than 6 hours, to take the missed dose right away and take the next dose as usual. If a dose of Zydelig is missed by more than 6 hours, advise patients to wait and take the next dose at the usual time [see DOSAGE AND ADMINISTRATION].
Idelalisib was not carcinogenic in a 26-week study in transgenic mice when administered daily by oral gavage at doses up to 500 mg/kg/day in males and 1000 mg/kg/day in females. Idelalisib was not carcinogenic in a 2-year study in rats when administered daily by oral gavage at exposures 0.40/0.62-fold (male/female), compared to the exposure in patients with hematologic malignancies administered the recommended dose of 150 mg twice daily.
Idelalisib did not induce mutations in the bacterial mutagenesis (Ames) assay and was not clastogenic in the in vitro chromosome aberration assay using human peripheral blood lymphocytes. Idelalisib was genotoxic in males in the in vivo rat micronucleus study at a high dose of 2000 mg/kg.
Idelalisib may impair fertility in humans. In a fertility study, treated male rats (25, 50, or 100 mg/kg/day of idelalisib) were mated with untreated females. Decreased epididymidal and testicular weights were observed at all dose levels and reduced sperm concentration at the mid-and high doses; however, there were no adverse effects on fertility parameters. The low dose in males resulted in an exposure (AUC) that is approximately 50% of the exposure in patients at the recommended dose of 150 mg twice daily.
In a separate fertility study, treated female rats (25, 50, or 100 mg/kg/day of idelalisib) were mated with untreated males. There were no adverse effects on fertility parameters; however, there was a decrease in the number of live embryos at the high dose. The high dose in females resulted in an exposure (AUC) that is approximately 17-fold the exposure in patients at the recommended dose of 150 mg twice daily.
Based on findings in animal studies and the mechanism of action [see CLINICAL PHARMACOLOGY], Zydelig may cause fetal harm when administered to a pregnant woman.
There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of idelalisib to pregnant rats during organogenesis resulted in decreased fetal weight and congenital malformations in rats at maternal exposures (AUC) 12 times those reported in patients at the recommended dosage of 150 mg twice daily (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage of clinically recognized pregnancies 2-4% and 15-20%, respectively.
Animal Data
In an embryo-fetal development study in rats, pregnant animals receiving oral doses of idelalisib during the period of organogenesis (implantation to closure of the hard palate), embryo-fetal toxicities were observed at the mid-and high-doses that also resulted in maternal toxicity, based on reductions in maternal body weight gain. Adverse findings at idelalisib doses ≥ 75 mg/kg/day included decreased fetal weights, external malformations (short tail), and skeletal variations (delayed ossification and/or unossification of the skull, vertebrae, and sternebrae). Additional findings were observed at 150 mg/kg/day dose of idelalisib and included urogenital blood loss, complete resorption, increased post-implantation loss, and malformations (vertebral agenesis with anury, hydrocephaly, and microphthalmia/anophthalmia). The dose of 75 and 150 mg/kg/day of idelalisib in rats resulted in exposures (AUC) of approximately 12 and 30 times, respectively, the human exposure at the recommended dose of 150 mg twice daily.
There are no data on the presence of idelalisib or its metabolites in human milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with Zydelig and for 1 month after the last dose.
Zydelig may cause fetal harm when administered to a pregnant woman [see Use In Specific Populations].
Pregnancy testing is recommended for females of reproductive potential prior to starting Zydelig.
Females
Advise females of reproductive potential to use effective contraception during treatment with Zydelig and for 1 month after the last dose.
Males
Advise males with female partners of reproductive potential to use effective contraception during treatment with Zydelig and for 3 months after the last dose [see Nonclinical Toxicology].
Safety and effectiveness of Zydelig in pediatric patients have not been established.
Of the 490 patients with relapsed CLL who were treated with Zydelig in combination trials, 271 (55%) were 65 years of age and older. When comparing patients 65 years of age or older to younger patients with CLL, older patients had a higher incidence of discontinuation due to an adverse reaction (36% vs 28%), higher incidence of serious adverse reactions (73% vs 67%), and higher incidence of death (13% vs 9%).
No dose adjustment is recommended for patients with ALT or AST or bilirubin > upper limit of normal (ULN); however, limited safety and efficacy data are available for patients with baseline AST or ALT > 2.5 x ULN or bilirubin > 1.5 x ULN. Monitor patients with baseline hepatic impairment for adverse reactions [see WARNINGS AND PRECAUTIONS]. Follow dosage modifications for adverse reactions [see DOSAGE AND ADMINISTRATION].
No Information provided
Zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis, or patients with a history of toxic epidermal necrolysis with any drug [see WARNINGS AND PRECAUTIONS].
Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability.
At a dose 2.7 times the maximum recommended dose, Zydelig did not prolong the QT/QTc interval (i.e., ≤10 ms).
Idelalisib exposure increased in a less than dose-proportional manner over a dose range of 50 mg to 350 mg twice daily (0.3 to 2.3 times the approved recommended dosage).
Following 150 mg twice daily administration of idelalisib, average (% coefficient of variation) maximum concentrations (Cmax) and area under the curve (AUC) at steady-state were 1861 (43%) ng/mL and 10598 (41%) ng•h/mL for idelalisib.
The median time to peak concentration (Tmax) was observed at 1.5 hours.
Food Effect
The administration of a single dose of Zydelig with a high-fat meal (900 calories: 525 calories fat, 250 calories carbohydrates, and 125 calories protein) increased idelalisib AUC 1.4-fold relative to fasting conditions.
Protein binding of idelalisib is ≥ 84% with no concentration dependence.
The mean blood-to-plasma ratio was 0.7.
The apparent central volume of distribution at steady state is 23 L (%CV ~85%).
Idelalisib is a substrate of P-glycoprotein (P-gp) and BCRP in vitro.
The population apparent systemic clearance at steady-state is 14.9 L/hr (%CV ~ 38%). The population terminal elimination half-life of idelalisib is 8.2 hours.
Metabolism
Idelalisib is metabolized via aldehyde oxidase and CYP3A with additional minor metabolism by UGT1A4.
Excretion
Following a single 150 mg dose of radiolabeled idelalisib, 78% of the radioactivity was excreted in feces and 14% was excreted in the urine. Idelalisib is not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.
Age (18 to 91 years), sex, race (White, and non-Whites), renal impairment (creatinine clearance ≥ 15 mL/min) and weight (38 to 148 kg) had no effect on idelalisib exposure.
The mean AUC increased up to 1.7-fold in patients with hepatic impairment (defined as ALT or AST or bilirubin values ≥ ULN) compared to patients with normal hepatic function. There is limited information on idelalisib exposure in patients with baseline AST or ALT > 2.5 × ULN or bilirubin > 1.5 × ULN [see Specific Populations].
The coadministration of rifampin (strong CYP3A inducer and P-gp inducer) to healthy subjects decreased the mean idelalisib AUC by 75% and the mean Cmax by 58% [see DRUG INTERACTIONS].
The coadministration of ketoconazole (strong CYP3A inhibitor and P-gp inhibitor) to healthy subjects increased the mean idelalisib AUC by 1.8-fold. No changes in the mean Cmax were observed [see DRUG INTERACTIONS].
In vitro studies suggest that idelalisib inhibits CYP2C8, CYP2C19, and UGT1A1 and induces CYP2B6.
The mean Cmax of midazolam increased by 2.4-fold and the mean AUC of midazolam increased by 5.4-fold when midazolam (sensitive CYP3A substrate) was coadministered with Zydelig [see DRUG INTERACTIONS].
No changes in exposure to rosuvastatin (OATP1B1 and OATP1B3 substrate) or digoxin (P-glycoprotein substrate) were observed when coadministered with Zydelig.
Toxicities observed in animals and not reported in patients include cardiac toxicity (cardiomyopathy, inflammation, and increased heart weight) and pancreatic findings (inflammation, hemorrhage, and low-incidence acinar degeneration and hyperplasia). These findings were observed in Sprague-Dawley rats in toxicology studies at exposures (AUCs) higher than those reported in patients at the recommended dose of 150 mg twice daily. Cardiac inflammation was mainly seen in a 28-day study in rats, the other findings were observed in the 13-week and/or 6-month studies.
Zydelig was evaluated in a randomized, double-blind, placebo-controlled study GS-US312-0116 (referred to as 312-0116) (NCT01539512) in 220 patients with relapsed CLL who required treatment and were unable to tolerate standard chemoimmunotherapy due to coexisting medical conditions, reduced renal function as measured by creatinine clearance < 60 mL/min, or NCI CTCAE Grade ≥ 3 neutropenia or Grade ≥ 3 thrombocytopenia resulting from myelotoxic effects of prior therapy with cytotoxic agents. Patients were randomized 1:1 to receive 8 doses of rituximab (first dose at 375 mg/m2, subsequent doses at 500 mg/m2 every 2 weeks for 4 infusions and every 4 weeks for an additional 4 infusions) in combination with either an placebo taken orally twice daily or with Zydelig 150 mg taken orally twice daily until disease progression or unacceptable toxicity.
The median age was 71 years (range 47, 92) with 78% over 65, 66% were male, and 90% were White. The median time since diagnosis was 8.5 years. The median number of prior therapies was 3. Nearly all (96%) patients had received prior anti-CD20 monoclonal antibodies. The most common (>15%) prior regimens were: bendamustine + rituximab (BR) (98 patients, 45%), fludarabine + cyclophosphamide + rituximab (75 patients, 34%), single-agent rituximab (67 patients, 31%), fludarabine + rituximab (37 patients, 17%), and chlorambucil (36 patients, 16%). The median CIRS (Cumulative Illness Rating Scale) score was 8 (range 0-17), and 85% of patients had a score of >6. Median Karnofsky score was 80. Median estimated Creatinine Clearance (eCLcr) was 63.6 mL/min, with 41% of patients having an eCLcr of <60 mL/min. At screening, 19.5% of patients had a platelet count of <50 × 109/L, and 13.2% had an absolute neutrophil count (ANC) of <1 × 109/L.
The efficacy of Zydelig was based on progression free survival (PFS), as assessed by an independent review committee (IRC). The trial was stopped for efficacy following the first pre-specified interim analysis. Results of a second interim analysis continued to show a statistically significant improvement for Zydelig + R compared to placebo + R for the major efficacy outcome measure of PFS (HR: 0.18, 95% CI [0.10, 0.32], p < 0.0001).
At the final analysis, with a median follow-up of 8.3 months for the Zydelig + R group, and 5.6 months for the placebo + R group, the median PFS for the Zydelig + R group was 19.4 months (95% CI: 12.3, Not Reached) versus 6.5 months (95% CI: 4.0, 7.3) for the placebo + R group (HR: 0.15, 95% CI [0.09, 0.24], p < 0.0001).
Updated efficacy results are shown in Table 7 and the Kaplan-Meier curve for PFS is shown in Figure 1.
Table 7 : Efficacy Results from Study 312-0116
| Zydelig + R N = 110 |
Placebo + R N = 110 |
|
| PFS Median (months) (95% CI) | 19.4 (12.3, NR) | 6.5 (4.0, 7.3) |
| Hazard ratio (95% CI) | 0.15 (0.09, 0.24) | |
| P-value | < 0.0001 † | |
| ORR* (All PRs) | 92 (83.6%) | 17 (15.5%) |
| 95% CI | 75.4, 90.0 | 9.3, 23.6 |
| Odds Ratio (95% CI) | 27.8 (13.4, 57.5) | |
| P-value | <0.0001 | |
| DOR Median (months) (95% CI) | NR (12, NR) | 6.2 (2.8, 6.5) |
| PFS: progression-free survival; NR: not reached; ORR: overall response rate; PR: partial response; DOR: duration of response † The p value for PFS was based on stratified log-rank test. * ORR defined as the proportion of patients who achieved a complete response (CR) or PR. All PRs achieved; none of the patients achieved a CR. |
||
Figure 1 : Kaplan-Meier Plot of IRC-Assessed PFS for Study 312-0116
 |
ZYDELIG®
(zye-DEL-ig)
(idelalisib) tablets
What is the most important information I should know about Zydelig?
Zydelig can cause serious side effects that can lead to death, including:
If you have any of the above serious side effects during treatment with Zydelig, your healthcare provider may completely stop your treatment, stop your treatment for a period of time, or change your dose of Zydelig.
See “What are the possible side effects of Zydelig?” for more information about side effects.
What is Zydelig?
Zydelig is a prescription medicine used to treat people with chronic lymphocytic leukemia (CLL), in combination with rituximab, when CLL comes back after prior cancer treatment and when rituximab treatment alone may be used due to other health problems.
Zydelig should not be used as the first medicine to treat anyone, including people with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other slow growing (indolent) non-Hodgkin lymphomas.
Zydelig should not be used in combination with bendamustine and rituximab, or in combination with rituximab to treat people with FL, SLL, and other indolent non-Hodgkin lymphomas. It is not known if Zydelig is safe and effective in children.
Do not take Zydelig if you:
Before taking Zydelig, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements. Zydelig and certain other medicines may affect each other. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I take Zydelig?
What are the possible side effects of Zydelig?
The most common side effects of Zydelig when used in combination with rituximab include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Zydelig. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Zydelig?
Keep Zydelig and all medicines out of reach of children.
General information about the safe and effective use of Zydelig.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Zydelig for a condition for which it was not prescribed. Do not give Zydelig to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Zydelig that is written for health professionals.
What are the ingredients in Zydelig?
Active ingredient: idelalisib
Inactive ingredients: microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, and magnesium stearate. The tablet coating contains polyethylene glycol, talc, polyvinyl alcohol, titanium dioxide and FD&C Yellow #6 or Sunset Yellow FCF Aluminum Lake (for the 100 mg tablet) and red iron oxide (for the 150 mg tablet).
This Medication Guide has been approved by the U.S. Food and Drug Administration.
